Characteristics of Gut Microbiota and Therapeutic Effects in Patients with Ulcerative Colitis Under Time-Restricted Feeding Intervention

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500109396

Enrollment

Unknown

Registered

2025-09-17

Start date

2025-09-22

Completion date

Unknown

Last updated

2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Test Group:Participants will continue their prescribed medications (e.g., mesalazine) and, starting from the first day of treatment, undergo a 12-week time-restricted feeding (TRF) intervention. Durin

Control group:Participants will continue their prescribed medications (e.g., mesalazine) and, during the corresponding 12-week period, maintain their usual diet without any time restrictions.

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 60 years (18<= age < 60). 2. Diagnosis of ulcerative colitis (UC) according to the Chinese Consensus on Diagnosis and Treatment of Ulcerative Colitis (2023, Xi’an), with disease activity in mild (modified Mayo score 3–5) or moderate stage (modified Mayo score 6–10). 3. Willingness to voluntarily participate in the study, provide written informed consent, and complete follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with severe extraintestinal manifestations, a history of intestinal surgery, or who have received enteral or parenteral nutrition therapy within the past year (for disease duration <1 year, within the disease course). 2. Use of antibiotics, immunosuppressive therapy (including corticosteroids, immunosuppressants, biologics), probiotics, non-steroidal anti-inflammatory drugs (NSAIDs), or lipid-lowering drugs within the past month; or engaging in fasting, excessive exercise, or long-term insomnia behaviors. 3. Presence of diabetes, active malignancy within the past 5 years, active infection, severe respiratory or cardiac disease, acute or chronic kidney disease, psychiatric disorders, or impaired consciousness. 4. Pregnant or breastfeeding women.

Design outcomes

Primary

Measure	Time frame
Clinical remission rate in active UC patients;Endoscopic remission rate in active UC patients;	—

Secondary

Measure	Time frame
Clinical symptoms (fever, abdominal pain, general condition, etc.);Blood inflammatory markers (ESR and hsCRP);Gut fecal microbiota and metabolites;	—

Countries

China

Contacts

Public ContactTang Bo

The Second Affiliated Hospital of Army Medical University

botangxq@tmmu.edu.cn+86 158 2597 8285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026